How the mitochondrial protein ECSIT may drive brain cell damage in Alzheimer's
Understanding the role of ECSIT in neurodegeneration and Alzheimer's Disease
This project looks at whether changes in a mitochondrial protein called ECSIT cause nerve-cell damage in Alzheimer’s disease and could point to new ways to protect the brain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11092173 on NIH RePORTER |
What this research studies
Researchers will study how ECSIT controls mitochondrial health and production of damaging reactive oxygen in models that mimic Alzheimer’s disease. They will use laboratory experiments with cells and Alzheimer transgenic mice to see if ECSIT problems lead to the kind of brain changes seen in people with Alzheimer’s. The team will test whether fixing ECSIT-related pathways can reduce cell damage and Alzheimer-like symptoms in those models. Findings will guide whether ECSIT could become a target for future treatments or human studies.
Who could benefit from this research
Good fit: People living with Alzheimer’s disease or older adults at higher risk for Alzheimer’s could be appropriate candidates for future clinical studies or sample-donation efforts linked to this line of research.
Not a fit: Patients seeking immediate treatment changes or those with dementia from causes unrelated to mitochondrial dysfunction are unlikely to benefit directly from this laboratory-focused project right now.
Why it matters
Potential benefit: If successful, this work could identify a new biological target for therapies that protect brain cells and slow Alzheimer’s progression.
How similar studies have performed: Previous research has tied mitochondrial damage and oxidative stress to Alzheimer’s, but directly targeting ECSIT is a newer approach with limited prior clinical testing.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Ghosh, Sankar — Columbia University Health Sciences
- Study coordinator: Ghosh, Sankar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.